Autotaxin interacts with lipoprotein(a) and oxidized phospholipids in predicting the risk of calcific aortic valve stenosis in patients with coronary artery disease

Journal of Internal Medicine

Volumn 280, Issue 5, 2016, Pages 509-517

  Nsaibia, M J ^a   Mahmut, A ^a   Boulanger, M C ^a   Arsenault, B J ^b   Bouchareb, R ^a   Simard, S ^a   Witztum, J L ^c   Clavel, M A ^b   Pibarot, P ^b   Bosse Y ^b   Tsimikas, S ^c   Mathieu, P ^a  

^a LAVAL UNIVERSITY   (Canada)

^b UNIVERSITÉ LAVAL   (Canada)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

autotaxin; calcific aortic valve disease; calcific aortic valve stenosis; lipoprotein(a); oxidized phospholipids

Indexed keywords

APOLIPOPROTEIN B100; AUTOTAXIN; BIOLOGICAL MARKER; LIPOPROTEIN A; PHOSPHOLIPID; ALKYLGLYCEROPHOSPHOETHANOLAMINE PHOSPHODIESTERASE; PHOSPHODIESTERASE;

AGED; AORTA VALVE STENOSIS; ARTICLE; BLOOD VESSEL CALCIFICATION; CALCIFIC AORTIC VALVE STENOSIS; CASE CONTROL STUDY; CONFIDENCE INTERVAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; CORRELATION ANALYSIS; ENZYME ACTIVITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; ODDS RATIO; PREDICTIVE VALUE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN INTERACTION; RISK ASSESSMENT; RISK FACTOR; STATISTICAL ANALYSIS; AORTIC VALVE STENOSIS; BLOOD; COMPLICATION; OXIDATION REDUCTION REACTION;

AGED; AORTIC VALVE STENOSIS; APOLIPOPROTEIN B-100; CASE-CONTROL STUDIES; CORONARY ARTERY DISEASE; FEMALE; HUMANS; LIPOPROTEIN(A); MALE; OXIDATION-REDUCTION; PHOSPHOLIPIDS; PHOSPHORIC DIESTER HYDROLASES; RISK FACTORS;

EID: 84992018143     PISSN: 09546820     EISSN: 13652796     Source Type: Journal    
DOI: 10.1111/joim.12519     Document Type: Article

References (40)

1. Mathieu P, Boulanger MC. Basic mechanisms of calcific aortic valve disease. Can J Cardiol 2014; 30: 982–93.
2. Mohty D, Pibarot P, Despres JP et al. Age-related differences in the pathogenesis of calcific aortic stenosis: the potential role of resistin. Int J Cardiol 2010; 142: 126–32.
3. Stewart BF, Siscovick D, Lind BK et al. Clinical factors associated with calcific aortic valve disease. Cardiovascular Health Study. J Am Coll Cardiol 1997; 29: 630–4.
4. Eveborn GW, Schirmer H, Lunde P, Heggelund G, Hansen JB, Rasmussen K. Assessment of risk factors for developing incident aortic stenosis: the Tromso Study. Eur J Epidemiol 2014; 29: 567–75.
5. Capoulade R, Clavel MA, Dumesnil JG et al. Impact of metabolic syndrome on progression of aortic stenosis: influence of age and statin therapy. J Am Coll Cardiol 2012; 60: 216–23.
6. Derbali H, Bosse Y, Cote N et al. Increased biglycan in aortic valve stenosis leads to the overexpression of phospholipid transfer protein via Toll-like receptor 2. Am J Pathol 2010; 176: 2638–45.
7. Bosse Y, Miqdad A, Fournier D, Pepin A, Pibarot P, Mathieu P. Refining molecular pathways leading to calcific aortic valve stenosis by studying gene expression profile of normal and calcified stenotic human aortic valves. Circ Cardiovasc Genet 2009; 2: 489–98.
8. Mathieu P, Bouchareb R, Boulanger MC. Innate and adaptive immunity in calcific aortic valve disease. J Immunol Res 2015; 2015: 851945.
9. Hutcheson JD, Maldonado N, Aikawa E. Small entities with large impact: microcalcifications and atherosclerotic plaque vulnerability. Curr Opin Lipidol 2014; 25: 327–32.
10. Hasdai D, Lev EI, Behar S et al. Acute coronary syndromes in patients with pre-existing moderate to severe valvular disease of the heart: lessons from the Euro-Heart Survey of acute coronary syndromes. Eur Heart J 2003; 24: 623–9.
11. Thanassoulis G, Campbell CY, Owens DS et al. Genetic associations with valvular calcification and aortic stenosis. N Engl J Med 2013; 368: 503–12.
12. Kamstrup PR, Tybjaerg-Hansen A, Nordestgaard BG. Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population. J Am Coll Cardiol 2014; 63: 470–7.
13. Arsenault BJ, Boekholdt SM, Dube MP et al. Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort. Circ Cardiovasc Genet 2014; 7: 304–10.
14. Vongpromek R, Bos S, Ten Kate GJ et al. Lipoprotein(a) levels are associated with aortic valve calcification in asymptomatic patients with familial hypercholesterolaemia. J Intern Med 2015; 278: 166–73.
15. Mahmut A, Boulanger MC, El Husseini D et al. Elevated expression of lipoprotein-associated phospholipase A2 in calcific aortic valve disease: implications for valve mineralization. J Am Coll Cardiol 2014; 63: 460–9.
16. Lehti S, Kakela R, Horkko S et al. Modified lipoprotein-derived lipid particles accumulate in human stenotic aortic valves. PLoS One 2013; 8: e65810.
17. Choi J, Zhang W, Gu X et al. Lysophosphatidylcholine is generated by spontaneous deacylation of oxidized phospholipids. Chem Res Toxicol 2011; 24: 111–8.
18. Steinbrecher UP, Parthasarathy S, Leake DS, Witztum JL, Steinberg D. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc Natl Acad Sci USA 1984; 81: 3883–7.
19. Cote C, Pibarot P, Despres JP et al. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis. Heart 2008; 94: 1175–80.
20. Boutin JA, Ferry G. Autotaxin. Cell Mol Life Sci 2009; 66: 3009–21.
21. Schober A, Siess W. Lysophosphatidic acid in atherosclerotic diseases. Br J Pharmacol 2012; 167: 465–82.
22. Bouchareb R, Mahmut A, Nsaibia MJ et al. Autotaxin derived from lipoprotein(a) and valve interstitial cells promotes inflammation and mineralization of the aortic valve. Circulation 2015; 132: 677–90.
23. Capoulade R, Chan KL, Yeang C et al. Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis. J Am Coll Cardiol 2015; 66: 1236–46.
24. Gaudreault N, Ducharme V, Lamontagne M et al. Replication of genetic association studies in aortic stenosis in adults. Am J Cardiol 2011; 108: 1305–10.
25. Seman LJ, Breckenridge WC. Isolation and partial characterization of apolipoprotein (a) from human lipoprotein (a). Biochem Cell Biol 1986; 64: 999–1009.
26. Byun YS, Lee JH, Arsenault BJ et al. Relationship of oxidized phospholipids on apolipoprotein B-100 to cardiovascular outcomes in patients treated with intensive versus moderate atorvastatin therapy: the TNT trial. J Am Coll Cardiol 2015; 65: 1286–95.
27. Ferguson CG, Bigman CS, Richardson RD, van Meeteren LA, Moolenaar WH, Prestwich GD. Fluorogenic phospholipid substrate to detect lysophospholipase D/autotaxin activity. Org Lett 2006; 8: 2023–6.
28. Nordestgaard BG, Chapman MJ, Ray K et al. Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J 2010; 31: 2844–53.
29. Rogers MA, Aikawa E. A not-so-little role for Lp(a) in the development of calcific aortic valve disease. Circulation 2015; 132: 621–3.
30. Bergmark C, Dewan A, Orsoni A et al. A novel function of lipoprotein [a] as a preferential carrier of oxidized phospholipids in human plasma. J Lipid Res 2008; 49: 2230–9.
31. Siess W, Zangl KJ, Essler M et al. Lysophosphatidic acid mediates the rapid activation of platelets and endothelial cells by mildly oxidized low density lipoprotein and accumulates in human atherosclerotic lesions. Proc Natl Acad Sci USA 1999; 96: 6931–6.
32. Stracke ML, Krutzsch HC, Unsworth EJ et al. Identification, purification, and partial sequence analysis of autotaxin, a novel motility-stimulating protein. J Biol Chem 1992; 267: 2524–9.
33. Mills GB, Moolenaar WH. The emerging role of lysophosphatidic acid in cancer. Nat Rev Cancer 2003; 3: 582–91.
34. Aoki J, Inoue A, Okudaira S. Two pathways for lysophosphatidic acid production. Biochim Biophys Acta 2008; 1781: 513–8.
35. Tokumura A, Majima E, Kariya Y et al. Identification of human plasma lysophospholipase D, a lysophosphatidic acid-producing enzyme, as autotaxin, a multifunctional phosphodiesterase. J Biol Chem 2002; 277: 39436–42.
36. Dusaulcy R, Rancoule C, Gres S et al. Adipose-specific disruption of autotaxin enhances nutritional fattening and reduces plasma lysophosphatidic acid. J Lipid Res 2011; 52: 1247–55.
37. Rancoule C, Dusaulcy R, Treguer K, Gres S, Attane C, Saulnier-Blache JS. Involvement of autotaxin/lysophosphatidic acid signaling in obesity and impaired glucose homeostasis. Biochimie 2014; 96: 140–3.
38. Wu JM, Xu Y, Skill NJ et al. Autotaxin expression and its connection with the TNF-alpha-NF-kappaB axis in human hepatocellular carcinoma. Mol Cancer 2010; 9: 71.
39. Giganti A, Rodriguez M, Fould B et al. Murine and human autotaxin alpha, beta, and gamma isoforms: gene organization, tissue distribution, and biochemical characterization. J Biol Chem 2008; 283: 7776–89.
40. Saga H, Ohhata A, Hayashi A et al. A novel highly potent autotaxin/ENPP2 inhibitor produces prolonged decreases in plasma lysophosphatidic acid formation in vivo and regulates urethral tension. PLoS One 2014; 9: e93230.